면역 체크포인트 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "면역 체크포인트" in Korean language version.

refsWebsite

Global rank Korean rank

41nih.gov

4^th place

41doi.org

2^nd place

3^rd place

4web.archive.org

1^st place

1tang-prize.org

low place

1theguardian.com

12^th place

65^th place

1celldex.com

low place

1bloomberg.com

99^th place

156^th place

1nektar.com

low place

1immuno-oncologynews.com

low place

1pieris.com

low place

1astrazeneca.com

low place

1tgtherapeutics.com

low place

1worldcat.org

5^th place

11^th place

1macrogenics.com

low place

1clinicaltrials.gov

5,225^th place

4,327^th place

1economist.com

254^th place

191^st place

astrazeneca.com

“Q1 2015 Result” (PDF). AstraZeneca. 2015년 4월 24일. 2015년 6월 5일에 확인함.

bloomberg.com

“Cancer 'Miracle' Patients Studied Anew for Disease Clues”. 《Bloomberg》. 2014년 4월 12일. 2015년 6월 25일에 확인함.

celldex.com

“CDX-1127 – Monoclonal Antibody Targeting CD27”. Celldex Therapeutics. 2018년 10월 3일에 원본 문서에서 보존된 문서. 2015년 6월 4일에 확인함.

clinicaltrials.gov

Clinical trial number NCT01968109 for "Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors" - ClinicalTrials.gov

doi.org

dx.doi.org

“The blockade of immune checkpoints in cancer immunotherapy”. 《Nature Reviews. Cancer》 12 (4): 252–264. March 2012. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
“CD27 is required for generation and long-term maintenance of T cell immunity”. 《Nature Immunology》 1 (5): 433–440. November 2000. doi:10.1038/80877. PMID 11062504.
“Memory B cells and CD27”. 《Histology and Histopathology》 15 (2): 573–576. April 2000. doi:10.14670/HH-15.573. PMID 10809378.
“CD27 and CD70 in T cell and B cell activation”. 《Current Opinion in Immunology》 17 (3): 275–281. June 2005. doi:10.1016/j.coi.2005.04.004. PMID 15886117.
“The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity”. 《Immunity》 38 (1): 53–65. January 2013. doi:10.1016/j.immuni.2012.09.009. PMID 23159439.
“Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice”. 《Journal of Immunology》 191 (8): 4174–4183. October 2013. doi:10.4049/jimmunol.1300409. PMID 24026078.
“Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells”. 《British Journal of Pharmacology》 161 (3): 512–526. October 2010. doi:10.1111/j.1476-5381.2010.00922.x. PMC 2990151. PMID 20880392.
“CD40 and dendritic cell function”. 《Critical Reviews in Immunology》 23 (1–2): 83–107. 2003년 1월 1일. doi:10.1615/critrevimmunol.v23.i12.50. PMID 12906261.
“The role of interleukin-2 during homeostasis and activation of the immune system”. 《Nature Reviews. Immunology》 12 (3): 180–190. February 2012. doi:10.1038/nri3156. PMID 22343569.
“Anti-CD137 antibodies in the treatment of autoimmune disease and cancer”. 《Immunologic Research》 29 (1–3): 197–208. 2004년 6월 1일. doi:10.1385/ir:29:1-3:197. PMID 15181282.
“The significance of OX40 and OX40L to T-cell biology and immune disease”. 《Immunological Reviews》 229 (1): 173–191. May 2009. doi:10.1111/j.1600-065x.2009.00766.x. PMC 2729757. PMID 19426222.
“Science gone translational: the OX40 agonist story”. 《Immunological Reviews》 244 (1): 218–231. November 2011. doi:10.1111/j.1600-065x.2011.01069.x. PMC 3622727. PMID 22017441.
“OX40 is a potent immune-stimulating target in late-stage cancer patients”. 《Cancer Research》 73 (24): 7189–7198. December 2013. doi:10.1158/0008-5472.can-12-4174. PMC 3922072. PMID 24177180.
“GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations”. 《European Journal of Immunology》 34 (3): 613–622. March 2004. doi:10.1002/eji.200324804. PMID 14991590.
“GITR/GITRL: more than an effector T cell co-stimulatory system”. 《European Journal of Immunology》 37 (5): 1165–1169. May 2007. doi:10.1002/eji.200636933. PMID 17407102.
“GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability”. 《Cancer Immunology Research》 1 (5): 320–331. November 2013. doi:10.1158/2326-6066.cir-13-0086. PMC 3885345. PMID 24416730.
“ICOS controls the pool size of effector-memory and regulatory T cells”. 《Journal of Immunology》 180 (2): 774–782. January 2008. doi:10.4049/jimmunol.180.2.774. PMID 18178815.
“A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy”. 《Computational and Structural Biotechnology Journal》 13: 265–272. 2015년 4월 8일. doi:10.1016/j.csbj.2015.03.008. PMC 4415113. PMID 25941561.
“A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models”. 《Journal for Immunotherapy of Cancer》 10 (5): e004592. May 2022. doi:10.1136/jitc-2022-004592. PMC 9115112. PMID 35580926.
Prieto-Díaz, Rubén; González-Gómez, Manuel; Fojo-Carballo, Hugo; Azuaje, Jhonny; El Maatougui, Abdelaziz; Majellaro, Maria; Loza, María I.; Brea, José; Fernández-Dueñas, Víctor (2022년 12월 14일). “Exploring the Effect of Halogenation in a Series of Potent and Selective A 2B Adenosine Receptor Antagonists”. 《Journal of Medicinal Chemistry》 (영어) 66 (1): 890–912. doi:10.1021/acs.jmedchem.2c01768. ISSN 0022-2623. PMC 9841532. PMID 36517209.
“Adenosine A_2A receptor ligand recognition and signaling is blocked by A_2B receptors”. 《Oncotarget》 9 (17): 13593–13611. March 2018. doi:10.18632/oncotarget.24423. PMC 5862601. PMID 29568380.
“B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production”. 《Nature Immunology》 2 (3): 269–274. March 2001. doi:10.1038/85339. PMID 11224528.
“B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction”. 《European Journal of Immunology》 39 (7): 1754–1764. July 2009. doi:10.1002/eji.200839028. PMC 2978551. PMID 19544488.
“B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer”. 《Oncotarget》 6 (5): 3452–3461. February 2015. doi:10.18632/oncotarget.3097. PMC 4413666. PMID 25609202.
“Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses”. 《Cancer Research》 73 (15): 4820–4829. August 2013. doi:10.1158/0008-5472.can-12-3457. PMC 3732560. PMID 23722540.
“BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination”. 《The Journal of Clinical Investigation》 120 (1): 157–167. January 2010. doi:10.1172/jci40070. PMC 2799219. PMID 20038811.
“CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice”. 《Arthritis and Rheumatism》 60 (1): 123–132. January 2009. doi:10.1002/art.24181. PMID 19116935.
“De-novo and acquired resistance to immune checkpoint targeting”. 《The Lancet. Oncology》 18 (12): e731–e741. December 2017. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
“Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer”. 《Cancer Immunology, Immunotherapy》 63 (7): 721–735. July 2014. doi:10.1007/s00262-014-1549-4. PMC 4384696. PMID 24711084.
“Role of LAG-3 in regulatory T cells”. 《Immunity》 21 (4): 503–513. October 2004. doi:10.1016/j.immuni.2004.08.010. PMID 15485628.
“LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems”. 《The Journal of Clinical Investigation》 117 (11): 3383–3392. November 2007. doi:10.1172/jci31184. PMC 2000807. PMID 17932562.
“NOX2 in autoimmunity, tumor growth and metastasis”. 《The Journal of Pathology》 247 (2): 151–154. February 2019. doi:10.1002/path.5175. PMC 6587556. PMID 30270440.
“Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies”. 《International Immunology》 27 (1): 39–46. January 2015. doi:10.1093/intimm/dxu095. PMID 25323844.
“TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines”. 《European Journal of Immunology》 39 (9): 2492–2501. September 2009. doi:10.1002/eji.200939274. PMC 2759376. PMID 19676072.
“TIM-3 and its regulatory role in immune responses”. 《Current Topics in Microbiology and Immunology》 350: 1–15. 2010년 8월 11일. doi:10.1007/82_2010_84. ISBN 978-3-642-19544-0. PMID 20700701.
“VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses”. 《The Journal of Experimental Medicine》 208 (3): 577–592. March 2011. doi:10.1084/jem.20100619. PMC 3058578. PMID 21383057.
“VISTA is an immune checkpoint molecule for human T cells”. 《Cancer Research》 74 (7): 1924–1932. April 2014. doi:10.1158/0008-5472.CAN-13-1504. PMC 3979527. PMID 24691993.
“Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells”. 《The Journal of Clinical Investigation》 128 (11): 4912–4923. November 2018. doi:10.1172/JCI120612. PMC 6205408. PMID 30130255.
“Siglecs and their roles in the immune system”. 《Nature Reviews. Immunology》 7 (4): 255–266. April 2007. doi:10.1038/nri2056. PMID 17380156.
“Siglec-mediated regulation of immune cell function in disease”. 《Nature Reviews. Immunology》 14 (10): 653–666. October 2014. doi:10.1038/nri3737. PMC 4191907. PMID 25234143.
“The blockade of immune checkpoints in cancer immunotherapy”. 《Nature Reviews. Cancer》 12 (4): 252–264. March 2012. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.

economist.com

“Cancer drugs are getting better and dearer”. 《The Economist》. 2017년 5월 4일. 2017년 5월 19일에 확인함.

immuno-oncologynews.com

Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Clinical Trial

macrogenics.com

ir.macrogenics.com

“MacroGenics Provides Update on Corporate Progress and First Quarter 2015 Financial Results”. MacroGenics. 2015년 5월 6일. 2015년 6월 5일에 확인함.

nektar.com

ir.nektar.com

“Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine”. 《Nektar Therapeutics》. 2015년 6월 2일. 2017년 12월 19일에 원본 문서에서 보존된 문서. 2015년 6월 25일에 확인함.

nih.gov

ncbi.nlm.nih.gov

“The blockade of immune checkpoints in cancer immunotherapy”. 《Nature Reviews. Cancer》 12 (4): 252–264. March 2012. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
“CD27 is required for generation and long-term maintenance of T cell immunity”. 《Nature Immunology》 1 (5): 433–440. November 2000. doi:10.1038/80877. PMID 11062504.
“Memory B cells and CD27”. 《Histology and Histopathology》 15 (2): 573–576. April 2000. doi:10.14670/HH-15.573. PMID 10809378.
“CD27 and CD70 in T cell and B cell activation”. 《Current Opinion in Immunology》 17 (3): 275–281. June 2005. doi:10.1016/j.coi.2005.04.004. PMID 15886117.
“The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity”. 《Immunity》 38 (1): 53–65. January 2013. doi:10.1016/j.immuni.2012.09.009. PMID 23159439.
“Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice”. 《Journal of Immunology》 191 (8): 4174–4183. October 2013. doi:10.4049/jimmunol.1300409. PMID 24026078.
“Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells”. 《British Journal of Pharmacology》 161 (3): 512–526. October 2010. doi:10.1111/j.1476-5381.2010.00922.x. PMC 2990151. PMID 20880392.
“CD40 and dendritic cell function”. 《Critical Reviews in Immunology》 23 (1–2): 83–107. 2003년 1월 1일. doi:10.1615/critrevimmunol.v23.i12.50. PMID 12906261.
“The role of interleukin-2 during homeostasis and activation of the immune system”. 《Nature Reviews. Immunology》 12 (3): 180–190. February 2012. doi:10.1038/nri3156. PMID 22343569.
“Anti-CD137 antibodies in the treatment of autoimmune disease and cancer”. 《Immunologic Research》 29 (1–3): 197–208. 2004년 6월 1일. doi:10.1385/ir:29:1-3:197. PMID 15181282.
“The significance of OX40 and OX40L to T-cell biology and immune disease”. 《Immunological Reviews》 229 (1): 173–191. May 2009. doi:10.1111/j.1600-065x.2009.00766.x. PMC 2729757. PMID 19426222.
“Science gone translational: the OX40 agonist story”. 《Immunological Reviews》 244 (1): 218–231. November 2011. doi:10.1111/j.1600-065x.2011.01069.x. PMC 3622727. PMID 22017441.
“OX40 is a potent immune-stimulating target in late-stage cancer patients”. 《Cancer Research》 73 (24): 7189–7198. December 2013. doi:10.1158/0008-5472.can-12-4174. PMC 3922072. PMID 24177180.
“GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations”. 《European Journal of Immunology》 34 (3): 613–622. March 2004. doi:10.1002/eji.200324804. PMID 14991590.
“GITR/GITRL: more than an effector T cell co-stimulatory system”. 《European Journal of Immunology》 37 (5): 1165–1169. May 2007. doi:10.1002/eji.200636933. PMID 17407102.
“GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability”. 《Cancer Immunology Research》 1 (5): 320–331. November 2013. doi:10.1158/2326-6066.cir-13-0086. PMC 3885345. PMID 24416730.
“ICOS controls the pool size of effector-memory and regulatory T cells”. 《Journal of Immunology》 180 (2): 774–782. January 2008. doi:10.4049/jimmunol.180.2.774. PMID 18178815.
“A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy”. 《Computational and Structural Biotechnology Journal》 13: 265–272. 2015년 4월 8일. doi:10.1016/j.csbj.2015.03.008. PMC 4415113. PMID 25941561.
“A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models”. 《Journal for Immunotherapy of Cancer》 10 (5): e004592. May 2022. doi:10.1136/jitc-2022-004592. PMC 9115112. PMID 35580926.
Prieto-Díaz, Rubén; González-Gómez, Manuel; Fojo-Carballo, Hugo; Azuaje, Jhonny; El Maatougui, Abdelaziz; Majellaro, Maria; Loza, María I.; Brea, José; Fernández-Dueñas, Víctor (2022년 12월 14일). “Exploring the Effect of Halogenation in a Series of Potent and Selective A 2B Adenosine Receptor Antagonists”. 《Journal of Medicinal Chemistry》 (영어) 66 (1): 890–912. doi:10.1021/acs.jmedchem.2c01768. ISSN 0022-2623. PMC 9841532. PMID 36517209.
“Adenosine A_2A receptor ligand recognition and signaling is blocked by A_2B receptors”. 《Oncotarget》 9 (17): 13593–13611. March 2018. doi:10.18632/oncotarget.24423. PMC 5862601. PMID 29568380.
“B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production”. 《Nature Immunology》 2 (3): 269–274. March 2001. doi:10.1038/85339. PMID 11224528.
“B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction”. 《European Journal of Immunology》 39 (7): 1754–1764. July 2009. doi:10.1002/eji.200839028. PMC 2978551. PMID 19544488.
“B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer”. 《Oncotarget》 6 (5): 3452–3461. February 2015. doi:10.18632/oncotarget.3097. PMC 4413666. PMID 25609202.
“Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses”. 《Cancer Research》 73 (15): 4820–4829. August 2013. doi:10.1158/0008-5472.can-12-3457. PMC 3732560. PMID 23722540.
“BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination”. 《The Journal of Clinical Investigation》 120 (1): 157–167. January 2010. doi:10.1172/jci40070. PMC 2799219. PMID 20038811.
“CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice”. 《Arthritis and Rheumatism》 60 (1): 123–132. January 2009. doi:10.1002/art.24181. PMID 19116935.
“De-novo and acquired resistance to immune checkpoint targeting”. 《The Lancet. Oncology》 18 (12): e731–e741. December 2017. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
“Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer”. 《Cancer Immunology, Immunotherapy》 63 (7): 721–735. July 2014. doi:10.1007/s00262-014-1549-4. PMC 4384696. PMID 24711084.
“Role of LAG-3 in regulatory T cells”. 《Immunity》 21 (4): 503–513. October 2004. doi:10.1016/j.immuni.2004.08.010. PMID 15485628.
“LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems”. 《The Journal of Clinical Investigation》 117 (11): 3383–3392. November 2007. doi:10.1172/jci31184. PMC 2000807. PMID 17932562.
“NOX2 in autoimmunity, tumor growth and metastasis”. 《The Journal of Pathology》 247 (2): 151–154. February 2019. doi:10.1002/path.5175. PMC 6587556. PMID 30270440.
“Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies”. 《International Immunology》 27 (1): 39–46. January 2015. doi:10.1093/intimm/dxu095. PMID 25323844.
“TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines”. 《European Journal of Immunology》 39 (9): 2492–2501. September 2009. doi:10.1002/eji.200939274. PMC 2759376. PMID 19676072.
“TIM-3 and its regulatory role in immune responses”. 《Current Topics in Microbiology and Immunology》 350: 1–15. 2010년 8월 11일. doi:10.1007/82_2010_84. ISBN 978-3-642-19544-0. PMID 20700701.
“VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses”. 《The Journal of Experimental Medicine》 208 (3): 577–592. March 2011. doi:10.1084/jem.20100619. PMC 3058578. PMID 21383057.
“VISTA is an immune checkpoint molecule for human T cells”. 《Cancer Research》 74 (7): 1924–1932. April 2014. doi:10.1158/0008-5472.CAN-13-1504. PMC 3979527. PMID 24691993.
“Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells”. 《The Journal of Clinical Investigation》 128 (11): 4912–4923. November 2018. doi:10.1172/JCI120612. PMC 6205408. PMID 30130255.
“Siglecs and their roles in the immune system”. 《Nature Reviews. Immunology》 7 (4): 255–266. April 2007. doi:10.1038/nri2056. PMID 17380156.
“Siglec-mediated regulation of immune cell function in disease”. 《Nature Reviews. Immunology》 14 (10): 653–666. October 2014. doi:10.1038/nri3737. PMC 4191907. PMID 25234143.
“The blockade of immune checkpoints in cancer immunotherapy”. 《Nature Reviews. Cancer》 12 (4): 252–264. March 2012. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.

pieris.com

“Pieris Pharmaceuticals to present data on novel anti-CD137 and HER2 bispecific immuno-oncology program at UBS Global Healthcare Conference”. Pieris Pharmaceuticals. 2015년 5월 19일. 2018년 10월 3일에 원본 문서에서 보존된 문서. 2015년 6월 5일에 확인함.

tang-prize.org

“2014 Tang Prize in Biopharmaceutical Science”. 2017년 10월 20일에 원본 문서에서 보존된 문서. 2016년 6월 18일에 확인함.

tgtherapeutics.com

ir.tgtherapeutics.com

“TG Therapeutics Enters Into a Global Collaboration With Checkpoint Therapeutics to Develop and Commercialize Novel Immuno-Oncology Targeted Antibodies”. TG Therapeutics. 2015년 3월 4일. 2015년 6월 5일에 확인함.

theguardian.com

“James P Allison and Tasuku Honjo win Nobel prize for medicine”. 《the Guardian》. 2018년 10월 1일. 2018년 10월 1일에 확인함.

web.archive.org

“2014 Tang Prize in Biopharmaceutical Science”. 2017년 10월 20일에 원본 문서에서 보존된 문서. 2016년 6월 18일에 확인함.
“CDX-1127 – Monoclonal Antibody Targeting CD27”. Celldex Therapeutics. 2018년 10월 3일에 원본 문서에서 보존된 문서. 2015년 6월 4일에 확인함.
“Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine”. 《Nektar Therapeutics》. 2015년 6월 2일. 2017년 12월 19일에 원본 문서에서 보존된 문서. 2015년 6월 25일에 확인함.
“Pieris Pharmaceuticals to present data on novel anti-CD137 and HER2 bispecific immuno-oncology program at UBS Global Healthcare Conference”. Pieris Pharmaceuticals. 2015년 5월 19일. 2018년 10월 3일에 원본 문서에서 보존된 문서. 2015년 6월 5일에 확인함.

worldcat.org

Prieto-Díaz, Rubén; González-Gómez, Manuel; Fojo-Carballo, Hugo; Azuaje, Jhonny; El Maatougui, Abdelaziz; Majellaro, Maria; Loza, María I.; Brea, José; Fernández-Dueñas, Víctor (2022년 12월 14일). “Exploring the Effect of Halogenation in a Series of Potent and Selective A 2B Adenosine Receptor Antagonists”. 《Journal of Medicinal Chemistry》 (영어) 66 (1): 890–912. doi:10.1021/acs.jmedchem.2c01768. ISSN 0022-2623. PMC 9841532. PMID 36517209.